Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2014


#222012

N/A

DelveInsight

$ 1250

In Stock


The Report will be Dispatched in 3 Working Days. 

DelveInsights, Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Hormone Refractory Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Hormone Refractory Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope 

  • The report provides a snapshot of the global therapeutic landscape of  Metastatic Hormone Refractory Prostate Cancer
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the  Metastatic Hormone Refractory Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for  Metastatic Hormone Refractory Prostate Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects 
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages 
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy 

  • Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Hormone Refractory Prostate Cancer
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Devise corrective measures for pipeline projects by understanding  Metastatic Hormone Refractory Prostate Cancer pipeline depth and focus of Indication therapeutics  
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies  
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Content

Metastatic Hormone Refractory Prostate Cancer Overview
Metastatic Hormone Refractory Prostate Cancer Pipeline Therapeutics
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Development by Companies
Metastatic Hormone Refractory Prostate Cancer Late Stage Products (Filed and Phase III)
Comparative Analysis
Metastatic Hormone Refractory Prostate Cancer Mid Clinical Stage Products (Phase II)
Comparative Analysis
Metastatic Hormone Refractory Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
Metastatic Hormone Refractory Prostate Cancer Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Metastatic Hormone Refractory Prostate Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Metastatic Hormone Refractory Prostate Cancer Discontinued Products
Metastatic Hormone Refractory Prostate Cancer Dormant Products
Companies Involved in Therapeutics Development for Metastatic Hormone Refractory Prostate Cancer

Appendix
Methodology
Contact Us
Disclaimer

Number of Products under Development for Metastatic Hormone Refractory Prostate Cancer, 2014
Number of Products under Development by Companies 
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
Drug Candidates Profiles
Metastatic Hormone Refractory Prostate Cancer Assessment by Monotherapy Products 
Metastatic Hormone Refractory Prostate Cancer Assessment by Combination Products 
Metastatic Hormone Refractory Prostate Cancer Assessment by Route of Administration 
Metastatic Hormone Refractory Prostate Cancer Assessment by Stage and Route of Administration 
Metastatic Hormone Refractory Prostate Cancer Assessment by Molecule Type 
Metastatic Hormone Refractory Prostate Cancer Assessment by Stage and Molecule Type 
Metastatic Hormone Refractory Prostate Cancer Therapeutics Discontinued Products 
Metastatic Hormone Refractory Prostate Cancer Therapeutics Dormant Products
Products under Development by Companies, 2014

Number of Products under Development for Metastatic Hormone Refractory Prostate Cancer, 2014
Late Clinical Stage Products (Filed and Phase III), 2014
Mid Clinical Stage Products (Phase II), 2014
Early Clinical Stage Products (Phase I and IND Filed), 2014
Discovery and Pre-Clinical Stage Products, 2014
Metastatic Hormone Refractory Prostate Cancer Assessment by Monotherapy Products 
Metastatic Hormone Refractory Prostate Cancer Assessment by Combination Products 
Metastatic Hormone Refractory Prostate Cancer Assessment by Route of Administration 
Metastatic Hormone Refractory Prostate Cancer Assessment by Stage and Route of Administration 
Metastatic Hormone Refractory Prostate Cancer Assessment by Molecule Type 
Metastatic Hormone Refractory Prostate Cancer Assessment by Stage and Molecule Type